A novel derivative of xanomeline improved memory function in aged mice

Neuroscience Bulletin

Volumn 24, Issue 4, 2008, Pages 251-257

  Cui, Yi Hui ^a   Si, Wen ^a   Yin, Liang ^a   An, Shu Ming ^a   Jin, Jing ^a   Deng, Shi Ning ^a   Cao, Xiao Hua ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

EUK1001; Hippocampus; LD50; Long term potentiation; Memory; Xanomeline

Indexed keywords

3 [3 (3 FLOROPHENYL 2 PROPYN 1 YLTHIO) 1,2,5 THIADIAZOL 4 YL] 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE OXALATE; EUK 1001; MUSCARINIC M1 RECEPTOR AGONIST; XANOMELINE;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; BRAIN SLICE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; LD 50; LONG TERM MEMORY; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; RECOGNITION; TASK PERFORMANCE;

AGING; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; LETHAL DOSE 50; LONG-TERM POTENTIATION; MEMORY; MICE; MUSCARINIC AGONISTS; PYRIDINES; THIADIAZOLES;

EID: 48749112833     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-008-0204-5     Document Type: Article

References (24)

1. R.E. Tanzi L. Bertram 2005 Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120 545 555
2. R.T. Bartus 2000 On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis Exp Neurol 163 495 529
3. M.J. Knapp D.S. Knopman P.R. Solomon W.W. Pendlebury C.S. Davis S.I. Gracon 1994 A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The tacrine study group JAMA 271 985 991
4. R.D. Schwarz M.J. Callahan R.E. Davis J.C. Jaen H. Tecle 1997 Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: translation of in vitro selectivity to in vivo efficacy Drug Dev Res 40 133 143
5. A.L. Svensson U. Warpman E. Hellström-Lindahl N. Bogdanovic L. Lannfelt A. Nordberg 1997 Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes Neurosci Lett 232 37 40
6. A. Caccamo S. Oddo L.M. Billings K.N. Green H. Martinez-Coria A. Fisher 2006 M1 receptors play a central role in modulating AD-like pathology in transgenic mice Neuron 49 671 682
7. R.M. Eglen A. Choppin N. Watson 2001 Therapeutic opportunities from muscarinic receptor research Trends Pharmacol Sci 22 409 414
8. A. Christopoulos T.L. Pierce J.L. Sorman E.E. El-Fakahany 1998 On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor Mol Pharmacol 53 1120 1130
9. A. Christopoulos A.M. Parsons E.E. El-Fakahany 1999 Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor J Pharmacol Exp Ther 289 1220 1228
10. N. DeLapp S. Wu R. Belagaje E. Johnstone S. Little H. Shannon 1998 Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein(FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells Biochem Biophys Res Commun 244 156 160
11. N.C. Bodick W.W. Offen A.I. Levey N.R. Cutler S.G. Gauthier A. Satlin 1997 Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease Arch Neurol 54 465 473
12. S.M. William A.B. Kenneth D. Colleen A.E. Afif H. Ezdihar H. Nicola 2002 Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease Drug develop Res 57 200 213
13. X. Cao Z. Cui R. Feng Y.P. Tang Z. Qin B. Mei 2007 Maintenance of superior learning and memory function in NR2B transgenic mice during ageing Eur J Neurosci 25 1815 1822
14. A.C. Bartolomeo H. Morris J.J. Buccafusco N. Kille S. Rosenzweig-Lipson M.G. Husbands 2000 The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist J Pharmacol Exp Ther 292 584 596
15. J.J. Sramek A.J. Sedman P.A. Reece J. Hourani H. Bockbrader N.R. Cutler 1995 Safety and tolerability of CI-979 in patients with Alzheimer's disease Life Sci 57 503 510
16. W.S. Adamus J.P. Leonard W. Tröger 1995 Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease Life Sci 56 883 890
17. Cui YH, Wang D, Si W, Lv W, Niu Y, Lei XP, et al. Enhancement of memory function in aged mice by a novel derivative of xanomeline. Cell Res 2008, in press.
18. Y.P. Tang E. Shimizu G.R. Dube C. Rampon G.A. Kerchner M. Zhuo 1999 Genetic enhancement of learning and memory in mice Nature 401 63 69
19. E.C. Burgard J.M. Sarvey 1990 Muscarinic receptor activation facilitates the induction of long-term potentiation (LTP) in the rat dentate gyrus Neurosci Lett 116 34 39
20. E.W. Boddeke A. Enz G. Shapiro 1992 SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices Eur J Pharmacol 222 21 25
21. M.V. Sokolov A.M. Kleschevnikov 1995 Atropine suppresses associative potentiation in the hippocampus Brain Res 672 281 284
22. E.E. Avery L.D. Baker S. Asthana 1997 Potential role of muscarinic agonists in Alzheimer's disease Drug Aging 11 450 459
23. A.H. Dikinson J. Winkler J.L. Fisher H.J. Song M. Poo F.H. Gage 2003 Acetylcholine-secreting cells improve age-induced memory deficits Mol Ther 8 51 61
24. S.N. Burke C.A. Barnes 2006 Neural plasticity in the ageing brain Nat Rev Neurosci 7 30 40